News Focus
News Focus
Followers 48
Posts 7123
Boards Moderated 0
Alias Born 06/17/2009

Re: boi568 post# 328039

Sunday, 08/29/2021 3:22:35 PM

Sunday, August 29, 2021 3:22:35 PM

Post# of 519066
boi, in general, I … (author’s comments have been deleted).

As to the specific remarks (though some of your #'s are absent):

1) See frrol’s second point:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165674753

2) The initial announcement stated that the trial would be international in scope. Yet, it wasn’t until 50% enrollment was reached in Australia that other countries were “open for business.” I find that strange.

3) If you want to be like Biden, it is “C’mon, man.” Anyway, you nor anyone other than Dr. M and a few others know if a peek occurred. You are speculating like me; Dr. M said Anavex would be able to take a peek, thus, it is not 100% certainty, it hasn’t.

4) There is no argument, except from you, that waiting 18 months, more sufferers are going to deteriorate to such a point, that Blarcamesine will not help them. If the data were strong from the “peek,” then the regulatory agency that need more proof can dictate a P4 (open label, maybe) be conducted with the final results from the P3, but, at least, the product would be available for purchase by those who need it. [IMO, the data from the first 225 will be very strong and persuasive!]

5) C’mon, man! The trial numbers for the first 225 are set and ready for analysis (as well, as another 100 or so who have completed the trial since February, but should be in included in the “peek”). Plus, when the 75 placebo “victims” are analyzed in the OLE, there will be definitive results showing Blarcamesine’s strength.

6) I am not the one who is claiming an interim look will taint the numbers, so I don’t need to do any research. That job belongs to the claimant(s) to prove this fact. Investor points out in post #328048

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165674217

but, I claim the need to address AD’s mortality is as urgent as oncology’s if 18 months must be tacked on. During those 18 month, 900,000 American sufferers will die (using 10 years AD cycle); another 6 million in ROW, while the same numbers deteriorate to a point that they are not going find relief with Blarcamesine.

Another group that would benefit from a "peek," are the caretakers. They will start to have some relief from their exhausting job, too, especially, if the sufferers are able to go to the bathroom on their own.

Peace, boi, ... and BTW, you are no Bio!
Powerwalker


ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES!!!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News